A Survey of Recent Patents on CB2 Agonists in the Management of Pain
Gabriele Murineddu, Battistina Asproni and Gerard A. Pinna
Affiliation: Dipartimento di Scienze del Farmaco, Facolta di Farmacia, Universita degli Studi di Sassari, Via F. Muroni 23/A, 07100 Sassari, Italy.
Keywords: Cannabinoid, CB2 receptors, CB2 receptor ligands, chronic pain, neuropathic pain, inflammatory pain, BOEHRINGER INGELHEIM, Azacycloalkane Carboxamides, CARA THERAPEUTICS, Biphenylmethyl Ethyl Ureas
Pain, a homeostatic and protective mechanism which can go awry in disease states and therefore needs treatment, is a complex and differentiated sensorial perception which may be classified as physiological, inflammatory and neuropathic. Chronic pain represents a major health problem throughout the world, thus several companies and researchers have embarked on the search for new drugs and targets to treat the disease. The different types of receptors in the CNS involved in the mediation of analgesia include the cannabinoid receptors: in particular, CB2 modulators seem to represent a new potential class of analgesic. This review covers recent patents and advances in CB2 agonist studies in the management of pain.
Rights & PermissionsPrintExport